A proof‐of‐concept study with SOM3355 (bevantolol hydrochloride) for reducing chorea in Huntington's disease

Gámez, Josep; Calopa, Matilde; Muñoz, Esteban; Ferré Ferré, Aileen; Huertas, Óscar; H. McAllister, Kevin; Reig, Núria; Scart‐Grès, Catherine; Insa, R.; Kulisevsky, Jaime

doi:10.1111/bcp.15635

Public

A proof‐of‐concept study with SOM3355 (bevantolol hydrochloride) for reducing chorea in Huntington's disease

Published in British Journal of Clinical Pharmacology • Dec 10, 2022

Authors:

Josep Gámez

Matilde Calopa

Esteban Muñoz

Abstract

AIMS: -adrenoreceptor antagonist with recently identified vesicular monoamine transporter type 2 inhibitory properties, as a repositioned treatment to reduce chorea in Huntington's disease (HD). METHODS: A randomized, placebo-controlled proof-of-concept study was performed in 32 HD patients allocate...

Subject

Placebo

Chorea

Crossover study

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!